Kornimate/medical-research-clean huggingface dataset:
effect of short message service intervention on stent removal/exchange adherence in patients with benign pancreaticobiliary diseases

Conditions: Short Message Service; Adherence; Stent Exchange; ERCP; Biliary Stricture

Summary: endoscopic implantation of plastic or covered metal stents is widely used in a variety of benign pancreaticobiliary diseases, including duct stricture, large or difficult stones, bile or pancreatic juice leak, etc. there are some late-stage adverse events after stent insertion, such as stent occlusion, proximal or distal migration, secondary duct injury and failure of stent removal, etc. the longer the stents were inserted, more likely the adverse events would happen. although the optimal time of stent placement has not been well established, it has been recommended that plastic stent should be removed/exchanged within 3-4 months and covered metal stent be removed within 6 months. however, it was not uncommon that patients with stent implantation did not follow the recommendation of further stent management by endoscopists. many methods have been used to improve the adherence of patients in medical service. with the advance of mobile technology and popular use of mobile phones, it was believed that the patient-centered outcome could be improved by mobile telecommunication with the timely support of a patient by a health professional. thus we hypothesize that mobile technology, reminding the patients the necessity of stent management in time by short message service (sms), might increase the patient adherence in patients with benign pancreaticobiliary diseases after ercp.


Eligibility criteria:
inclusion criteria: * patients more than 18 years old with plastic or covered stent implantation for the drainage of bile or pancreatic juice. exclusion criteria: * primary or secondary sclerosing cholangitis; * malignant or suspected malignant stricture of biliary or pancreatic duct; * implantation of pancreatic duct stent for prevention of post-ercp pancreatitis; * expected survival time less than 6 months; * plan of surgery within 6 months; * pregnant or lactating women; * patients who could not give informed consent.
betaglucin 0.2% versus imiquimod 5% in treatment of ano-genital warts: combined results from triple blind controlled study

Conditions: Genital Wart Virus Infection

Summary: in order to determine the efficacy of betaglucin 0.2% in gel vs imiquimod 5% cream in the treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51 with betaglucin 0.2% and 51 with imiquimod 5%.

betaglucin soluble gel at 0.2% is produced in costa rica by a biochemical researcher. obtained by chemical process improves the immune response by increasing 80 times the number of macrophages and natural killer cells. specifically in human papillomavirus-related anogenital warts. as clinical researchers, the investigators pretend to determine the therapeutic efficacy of betaglucin 0.2 % gel compared with imiquimod 5% cream in two groups of individuals from 18 to 50 years old males and females. based in mathematics and biostatistics formula used by professor roman fentin, french academic working in the university of costa rica. medicine faculty in san jose the number of participants should be 102. divided into two arms. arm betaglucin 0.2% 51 individuals treated with betaglucin soluble gel at 0.2% arm imiquimod 5% 51 individuals treated with imiquimod cream at 5 % after three months of follow-up of all individuals, will be classified as clearance, partially cured and not cured. the plan of analysis will be: * chi-square test between the two groups (depending on the treatment) and the success or not of the treatment. * logistic model with a dependent variable the success or not of the treatment and with independent variables the treatment, sex, age. it will make it possible to verify that the differences observed in 1 are not due to another factor. * logistic model with a dependent variable the success or not of the treatment and with independent variables the treatment, the sex, the age, and an interaction sex-age. it will allow us to observe if there is a difference in the result according to the patient's sex.

Eligibility criteria:
inclusion criteria: * men and women aged 18 to 50 years with anogenital wart visible on physical examination and positive for hpv 6 and 11 by polymerase chain reaction (pcr) test with detection by agarose gel electrophoresis. exclusion criteria: * pregnant women. * vaccinated against human papillomavirus (gardasil, gardasil 9 or cervarix). * patients immunosuppressed by drugs (chemotherapy, corticoids, use of antibiotics for more than 7 days and/or antituberculous treatment.) * molluscum contagiosum. * skin appendages. * urethral prolapse. * botryoid sarcoma. * herpes type ii. * history of anogenital surgery in the last 4 weeks. * intake of natural products or immunomodulators. * patients who have received 5% imiquimod cream.

Keywords: betaglucin soluble gel ano-genital warts clearance human papillomavirus
10-year follow-up of clinical outcome after antipsychotic treatment discontinuation in psychosis individuals

Conditions: Schizophrenia; Schizophrenia Relapse; Schizophrenia Spectrum and Other Psychotic Disorders

Summary: this open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the ten years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with schizophrenia spectrum disorder.


Eligibility criteria:
inclusion criteria: * individuals included in the first episode psychosis clinical program (pafip) at the university hospital marqués de valdecilla (santander, spain). * a minimum of 18 months on antipsychotic treatment. * meeting clinical remission criteria for at least the 12 months prior to inclusion. * meeting the functional recovery criteria for at least the 6 months prior to inclusion. * stabilized at the lowest effective doses for at least the 3 months prior to inclusion. exclusion criteria: * meeting diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria for drug dependence. * meeting dsm-iv criteria for mental retardation. * having a history of neurological disease or head injury.

Keywords: treatment maintenance
near-infrared image guided surgical resection with indocyanine green in treating patients with head and neck cancer

Conditions: Head and Neck Carcinoma

Summary: this phase ib/ii trial studies the side effects of near-infrared image guided surgical resection with indocyanine green in treating patients with head and neck cancer. near-infrared image guided surgical resection with indocyanine green may make it easier to find and remove tumors.

primary objectives: i. to determine the safety profile of high-dose optical dye, indocyanine green, in head and neck cancer surgical patients. secondary objectives: i. determine the efficacy of high-dose indocyanine green to identify cancer compared to surrounding normal tissue (tumor to background ratio; tbr) in head and neck cancer resections. outline: patients receive indocyanine green intravenously (iv) on day 0 and undergo near-infrared image guided surgical resection on day 1. after completion of study treatment, patients are followed up for 14-30 days.

Eligibility criteria:
inclusion criteria: * documentation of a head and neck cancer diagnosis as evidenced by tissue biopsy. * patients diagnosed with any t stage, any subsite within the head and neck that are scheduled to undergo surgical resection. patients with recurrent disease or a new primary will be allowed. * planned standard of care surgery with curative intent for squamous cell carcinoma. * have life expectancy of more than 12 weeks. * karnofsky performance status of at least 70% or eastern cooperative oncology group (ecog)/zubrod level 1. * hemoglobin \>= 9 gm/dl. * white blood cell count \> 3000/mm\^3. * platelet count \>= 100,000/mm\^3. * serum creatinine =\< 1.5 mg/dl. * liver enzymes (aspartate aminotransferase \[ast\], alanine aminotransferase \[alt\], and total bilirubin) =\< 1.5 times the upper reference range. * written informed consent (and assent when applicable) obtained from subject or subject?s legal representative and ability for subject to comply with the requirements of the study. * agree to not have radioactive iodine uptake studies done within 1 week of indocyanine green. exclusion criteria: * pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. * allergy to iodine or iodinated materials. * presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. * myocardial infarction (mi); cerebrovascular accident (cva); uncontrolled congestive heart failure (chf); significant liver disease; or unstable angina within 6 months prior to enrollment.
creating healthy environments for chicago kids

Conditions: Childhood Obesity

Summary: pediatric obesity interventions for low-income populations are increasingly delivered in children's homes, which may make treatment more accessible to families and enhance the potency of the intervention in several ways. this randomized trial will directly test whether delivering family-based behavioral interventions for pediatric overweight/obesity in the home setting improves weight loss outcomes in low-income children relative to medical center-based treatment. the trial will also quantify the cost-effectiveness of home visitation, and explore the mechanisms accounting for observed treatment effects

the goal of this project is to systematically evaluate the incremental weight loss benefit and cost-effectiveness of delivering standard family-based treatment for pediatric overweight/obesity in the home setting vs. traditional medical settings. in a randomized controlled trial involving low-income households, 266 children ages 6-12 years will be allocated to 12 months of family-based treatment delivered either in their home or at an urban academic medical center. both arms will receive the same intervention content and dosage, and differ only in the location of in-person treatment sessions. aim 1 is to test the hypothesis that home-based treatment produces a greater reduction in child adiposity, reflected in 12-month change in bmi z-score. aim 2 is to compare the cost-effectiveness of home-based treatment to medical center-based treatment, and calculate the added cost of the incremental weight loss benefit associated with home visitation. these data will inform efforts to disseminate home-based interventions for low-income populations by public health agencies and third-party payers. aim 3 is to explore specific mechanisms through which home visitation may improve weight loss outcomes.

Eligibility criteria:
inclusion criteria: * family includes at least one child who is 6 to 12 years old, and is overweight or obese (has a body mass index at or above the 85th percentile for age and sex) * child's household has an income-to-poverty ratio ≤ 2.0 exclusion criteria: * child or caregiver(s) are not fluent in english * unwilling to attend and complete either home-based or clinic-based treatment, or to complete any aspect of the study assessment battery * medical contraindication or barrier to weight loss treatment * caregiver has a major medical or psychiatric condition likely to interfere with treatment * plans to relocate outside the chicago area in the next 12 months, or living in temporary or group housing with other families * resides more than 15 miles from the illinois medical district (study site) * conditions in or around the home that jeopardize staff/interventionist safety
telaprevir with peginterferon alfa & ribavirin in ex-people who inject drugs infected by genotype 1 chronic hepatitis c

Conditions: Hepatitis, Chronic

Summary: the purpose of this study is to collect information on the efficacy, safety and tolerability of telaprevir (in combination with other medications), in patients who have a history of intravenous drug use with genotype 1 chronic hepatitis c, under substitution therapy (eg., methadone, buprenorphine) and/or followed in addiction centres.

this is a multicenter, non-interventional, observational, prospective study to evaluate the efficacy, safety, and adherence to telaprevir in ex-people who inject drugs (ex-pwids) infected with genotype 1 chronic hepatitis c and any fibrosis stage including compensated cirrhosis, who are receiving substitution therapy (eg, methadone, buprenorphine) and/or are being followed in an addiction center. patients may be treatment naïve or relapsers. participating physicians are to offer enrollment in this study to all eligible patients at their site in who they plan to initiate triple therapy with telaprevir, pegylated interferon alfa (pegifn alfa), and ribavirin (rbv). a target of 115 patients will participate in this study. the duration of each patient's participation in this study will be up to approximately 60 weeks. after obtaining the signed participation agreement or icf, selection criteria will be reviewed to verify the patient's eligibility. data will be recorded in the electronic case report form (crf) at 6 time points for each patient which correspond to routine care visits: inclusion, and at the patient's routine care visit closest to week 4, 12, and 24, end of treatment, and end-of-follow-up (e.g., approximately 12 weeks after end-of-treatment). no additional blood, urine, or other biological samples will be required, and no additional investigations, beyond the routine clinical management of the patient, will be performed.

Eligibility criteria:
inclusion criteria: have hcv genotype 1, a quantifiable serum hcv rna, recent (within 18 months of baseline) documentation of the degree of liver fibrosis (metavir f0-f4; ishak 0-6) assessed by liver biopsy or non-invasive test (eg, fibrotest, fibroscan); physician decision to start triple therapy with telaprevir and pegifn alfa/rbv; have never been treated with antiviral treatment (naïve) or who have relapsed after ifn or pegifn plus rbv (relapsers); history of injecting drugs and are currently under stable substitution therapy (eg, methadone, buprenorphine) and/or followed in an addiction center. exclusion criteria: infected or coinfected with hcv of a genotype other than genotype 1; previous or current treatment with a daa therapy; have any contraindication specified in the smpc for telaprevir, pegifn alfa, or rbv; have a history or other evidence of decompensated liver disease, or have coinfection with active hepatitis b or hiv; currently participating in another investigational study or clinical study.

Keywords: hcv genotype 1 liver fibrosis ex-people who inject drugs (ex-pwids)
compare the effect of green tea mouthwash vs chlorohexidine mouthwash in children with plaque-induced gingivitis

Conditions: Plaque Induced Gingivitis

Summary: this study aims to assess and compare the effect of green tea mouthwash compared to chlorohexidine mouthwash in reducing gingivitis and plaque scores (in terms of plaque index and gingival index) in children with plaque-induced gingivitis.

this study aims to assess and compare the effect of green tea mouthwash compared to chlorohexidine mouthwash in reducing gingivitis and plaque scores (in terms of plaque index and gingival index) in children with plaque-induced gingivitis. this study will be conducted in the outpatient clinics of the pediatric dentistry and dental public health department - faculty of dentistry, cairo university - egypt. patients attending the outpatient clinic in pediatric dentistry and dental public health department - faculty of dentistry - cairo university - egypt will be screened until the target population is achieved.

Eligibility criteria:
inclusion criteria: * children aged 10-14 years. * children with a gingival index score of ≥ 1 and a plaque index score of ≥ 1. * children in good medical health and free from major oral hard or soft tissue lesions. \[medically fit children (asa i, ii)\]. * children classified as cooperative or potentially cooperative according to wright's classification of child behavior. * children mentally capable of communication. exclusion criteria: * parental refusal for participation. * children under antibiotics treatment during the last six weeks prior to the study. * children wearing fixed or removable orthodontic devices. * patients who underwent oral prophylaxis in the last six months.

Keywords: green tea
3/7 resistance training method in cardiac rehabilitation

Conditions: Heart Failure; Coronary Artery Disease

Summary: aim of the clinical monocentric study is to assess the resistance training exercise intervention in patients with heart failure with reduced ejection fraction (hfref) and coronary artery disease that will best improve peak oxygen uptake (peak vo2) and leg strength (assessed isokinetic). the investigators hypothesize that resistance training exercise with induced a high stress metabolic is more important exercise with induced than a lower stress metabolic.


Eligibility criteria:
inclusion criteria: * clinical coronary artery diseases * heart failure with reduced ejection fraction exclusion criteria: * angina * acutely decompensated heart failure * electrocardiographic evidence of ischemia * significant valvular disease * orthopedic/neurologic disorders that limited exercise

Keywords: cardiac rehabilitation resistance training strength training exercise for older adults
evaluation of missed osteoporosis diagnoses, and preference between once monthly ibandronate and once weekly alendronate

Conditions: Osteoporosis

Summary: this is a two part study (screening and treatment). the first part (screening) is designed to evaluate the percentage of patients missed in diagnosing osteoporosis by general practitioners (gp's). the second part (treatment) is designed to determine the preference by patients for the once monthly ibandronate or the once weekly alendronate.

a multi-centre, randomised, open-label, cross-over study to evaluate the percentage of false negative osteoporosis diagnoses using the standard case-finding procedure as described by the dutch institute for health care (cbo) and to determine the preference of adult osteoporosis patients between once monthly dosing of ibandronate (150 mg) and once weekly dosing of alendronate (70 mg).

Eligibility criteria:
inclusion criteria: * women registered with a gp, without a prior history of osteoporosis. according to a case-finding procedure, osteoporosis will be diagnosed or excluded. exclusion criteria: * abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia. * inability to stand or sit in the upright position for 60 minutes. * previous use of bone active agents (e.g. strontium, pth). * significant medical condition which may preclude the patient's ability to complete the study. * history of alcohol or drug abuse. * hypersensitivity to any component of the bisphosphonates alendronate and ibandronate. * administration of any investigational drug within 30 days preceding the first dose of the study drug. * serum total calcium \> 10.5 mg/dl or \< 8.0 mg/dl (equivalent to 2.63 mmol/l and 1.99 mmol/l). * osteoporosis by secondary causes, will be excluded especially when an isolated deformity of the vertebral body is detected during x-ray analysis.

Keywords: ibandronate osteoporosis preference case-finding post-menopausal alendronate
a research study about weight loss and treatment patterns with the use of saxenda® in adults in real-life settings in switzerland

Conditions: Obesity or Overweight

Summary: the study is investigating weight loss and treatment patterns associated with the use of saxenda® in adult patients. the aim of the study is to assess the weight loss associated with saxenda® in patients with obesity or overweight. saxenda® was prescribed to participants by study doctor independently of this study. the study will last for about 4 months, where the data will be collected from the available medical records. there will be no additional activities expected from participants in the scope of study because it is a chart-review study.


Eligibility criteria:
inclusion criteria: * signed consent (general consent for research or study-specific informed consent) obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * male or female, aged 18 to 74 years (both inclusive) at the time of saxenda® initiation. * have been prescribed saxenda® for weight management. * for the reimbursed cohort, per the swiss reimbursement criteria: bmi greater than or equal to 35 kg/m\^2 or a bmigreater than or equal to 28 and below 35 kg/m\^2 with additional weight related comorbidities (pre diabetes or t2d (type 2 diabetes mellitus), hypertension, dyslipidaemia), prior to receiving the saxenda® treatment. * for the non-reimbursed cohort, bmi greater than or equal to 30 kg/m\^2 or a bmi greater than or equal to 28 kg/m\^2 with additional weight related comorbidities (pre diabetes or t2d, arterial hypertension, dyslipidaemia), prior to receiving the saxenda® treatment. * the decision to initiate treatment with commercially available saxenda® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study. * baseline weight measurement within 3 months of saxenda® initiation/prescription. * at least one weight assessment post-saxenda® initiation/prescription. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study. * treatment with any investigational drug within 30 days of saxenda® prescription/initiation. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * concomitant treatment of saxenda® with other glp 1 (glucagon-like peptide-1) receptor agonists, or orlistat. * concomitant treatment with sodium/glucose cotransporter-2 inhibitors (sglt 2i), dipeptidyl peptidase-4 (dpp 4i), or insulin for the reimbursed cohort only. * patients who have been treated with any obesity medication for last 12 weeks prior to initiation of saxenda® treatment. * patients who have previously been treated with a glp 1 receptor agonist for the reimbursed cohort only. * patients who have undergone bariatric surgery at any time before starting saxenda® treatment. * patients initiating saxenda® treatment after 31 october 2020.